Cellares develops the Cell Shuttle™, a modular, cGMP platform that automates cell therapy manufacturing using a closed, single-use cartridge system. This technology increases productivity by tenfold and reduces costs by up to 50% compared to conventional contract development and manufacturing organizations (CDMOs), while also minimizing process failure rates.
Funding
$355M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KDFounders
Product
Problem
Current cell therapy manufacturing processes rely heavily on manual steps and open, labor-intensive workflows, leading to high costs, scalability challenges, and increased risk of contamination and process variability. Traditional contract development and manufacturing organizations (CDMOs) struggle to meet the growing demand for cell therapies due to these limitations.
Solution
Cellares offers an integrated development and manufacturing organization (IDMO) model powered by the Cell Shuttle, a modular, closed-system platform designed for automated cell therapy manufacturing. The Cell Shuttle utilizes single-use cartridges to streamline and automate the entire cell therapy manufacturing process, from cell isolation and activation to transduction, expansion, and fill/finish. This approach significantly increases manufacturing throughput, reduces per-batch costs, and minimizes process failure rates compared to conventional CDMOs. Cellares' IDMO smart factories provide comprehensive preclinical, clinical, and commercial services, enabling cell therapy developers to accelerate their programs and unlock the full potential of their therapies.
Target Audience
The primary target audience includes cell therapy developers, biotechnology companies, and pharmaceutical organizations seeking to streamline manufacturing, reduce costs, and improve the scalability and reliability of their cell therapy production.
Features
- Cell Shuttle: A modular, cGMP-compliant platform for industrial-scale cell therapy manufacturing.
- Single-use Cartridge: Enables true end-to-end automation in a closed and automated system.
- Cell Q: An automated, high-throughput QC platform for cell therapies.
- Integrated Software Suite: Provides flexible and fully integrated cell therapy manufacturing software.
- Smart Factories: Strategically located facilities offering preclinical, clinical, and commercial services.
- 10x increase in productivity compared to conventional CDMOs.
- Up to 50% reduction in cost per batch.
- 75% lower process failure rates.